Results 121 to 130 of about 16,022 (277)

Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine [PDF]

, 2020
Weize Huang, Lindsay C. Czuba, Nina Isoherranen   +2 more
openalex   +1 more source

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Quantitative systems pharmacology (QSP) models offer a useful platform to integrate drug pharmacology with knowledge about biological mechanisms across multiple scales and data sources into a unified quantitative framework. This makes them invaluable to address many relevant questions in drug research and development.
Johannes Tillil, Wilhelm Huisinga, Jane Knöchel   +2 more
wiley   +1 more source

Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project

CPT: Pharmacometrics & Systems Pharmacology
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways.
Julia Macente, Nina Nauwelaerts, Justine Marine Badée, Rodolfo Hernandes Bonan, Miao‐Chan Huang, Martje Van Neste, Anne Smits, Karel Allegaert, Hedvig Nordeng, Markus Hovd, Frederico Severino Martins, Pieter Annaert   +11 more
doaj   +1 more source

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I [PDF]

, 2022
Jakub Witkowski, Sebastian Polak, Zbigniew Rogulski, Dariusz Pawelec   +3 more
openalex   +1 more source

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach

Frontiers in Pharmacology
Purpose: This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and pulmonary EGFRm+ (T790M and L858R mutants) inhibition in Caucasian, Japanese,
Feng Liang, Yimei Zhang, Qian Xue, Na Yao   +3 more
doaj   +1 more source

Modeling Three-dimensional Invasive Solid Tumor Growth in Heterogeneous Microenvironment under Chemotherapy

, 2018
A systematic understanding of the evolution and growth dynamics of invasive solid tumors in response to different chemotherapy strategies is crucial for the development of individually optimized oncotherapy.
Chen, Guo, Fan, Qihui, Hai, Miaomiao, Hu, Zhijian, Jiao, Yang, Liu, Liyu, Liu, Ruchuan, Shuai, Jianwei, Xie, Hang, Yang, Jiaen, Yang, Yue   +10 more
core   +1 more source

PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population [PDF]

, 2023
Suvarchala Kiranmai Avvari, Jaclyn A. Cusumano, Vamshi Jogiraju, Pooja Manchandani, David R. Taft   +4 more
openalex   +1 more source

Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

International Journal of Nanomedicine
You Liang,* Bo Sun,* Min Yang, Xiaona Meng, Meng Wang, Lijuan Yang, Bandar AI-Hamyari, Yuqian Zhang, Yutong Shen, Shengnan Meng Department of Pharmaceutics, School of Pharmacy, China Medical University, Shenyang, 110122, People’s Republic of ...
Liang Y, Sun B, Yang M, Meng X, Wang M, Yang L, AI-Hamyari B, Zhang Y, Shen Y, Meng S   +9 more
doaj  

Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases

Scientific Reports
The purpose of this study was to develop and validate a physiologically based pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and the intracranial time-course ...
Feng Liang, Yimei Zhang, Qian Xue, Xiaoling Zhang   +3 more
doaj   +1 more source

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +1 more source